Indication for testing:
Recommended test to confirm a diagnosis of hereditary breast and/or ovarian cancer in individuals with a personal or family history of breast and/or ovarian cancer. 
Acceptable test to confirm HBOC syndrome (BRCA1 and BRCA2 genes only).
Pathogenic variants in multiple genes have been implicated in hereditary breast and/or ovarian cancer (HBOC). Hereditary cancer predisposition is often characterized by early age of onset (typically before age 50) and multiple, multifocal, and/or similar cancers in a single individual or in a closely related family member(s). Pathogenic variants in the genes analyzed by this panel cause variable phenotypes and cancer risks, including nonbreast/nonovarian cancers. Pathogenic variants in the BRCA1 and BRCA2 genes are associated with HBOC syndrome.
DISEASE OVERVIEW Associated Disorder

BRCA1-and BRCA2-associated HBOC syndrome
Individuals with a pathogenic BRCA1 or BRCA2 variant are at increased risk for breast, ovarian, fallopian, peritoneal, pancreatic, prostate, melanoma, and other cancers.
Etiology
At least 5-10% of all breast cancers and 10-15% of all ovarian cancers are associated with a hereditary cause. 
Inheritance
All genes tested on the HBOC panel are autosomal dominant with the exception of the MUTYH gene, which is autosomal recessive but may also have autosomal dominant risks that are not well defined.
Some genes are associated with autosomal recessive childhood cancer predisposition or other syndromes.
See Genes Tested table for genes included in the panel.
Clinical Sensitivity
Variable, dependent on phenotype/condition BRCA1 and BRCA2 sequencing and deletion/duplication testing alone detects 20-60% of HBOCs, in general. >80% of BRCA1 and BRCA2 variants are detectable by sequencing.
10% of BRCA1 and BRCA2 variants are detectable by large deletion/duplication analysis. 
TEST DESCRIPTION
1, 2 When a relative has a previously identified pathogenic sequence variant, see Familial Mutation, Targeted Sequencing (2001961).
Indication for testing:
Recommended test for a known familial sequence variant previously identified in a family member.
A copy of the family member's test result documenting the familial variant is required.
See Related Tests
TESTING STRATEGY Contraindications for Ordering
Should not be ordered to detect somatic variants associated with malignancy because sensitivity for mosaic variants is low with methodology used for germline assays. Individuals with hematological malignancy and/or a previous allogenic bone marrow transplant should not undergo molecular genetic testing on a peripheral blood specimen.
Testing of cultured fibroblasts is required for accurate interpretation of test results.
When a relative has a previously identified pathogenic variant, see Familial Mutation, Targeted Sequencing (2001961).
Limitations
A negative result does not exclude a heritable form of cancer. Diagnostic errors can occur due to rare sequence variations.
Interpretation of this test result may be impacted if this individual has had an allogeneic stem cell transplantation. 
Analytical Sensitivity
For BRCA1 and BRCA2 stand-alone testing: Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) of BRCA1 and BRCA2: 99%. 
